Incorporação do hormônio do crescimento humano recombinante (rhGH) em matriz de polímero biodegradável
Recombinant human growth hormone (rhGH) incorporated into biodegradable polymer scaffolds
Garcia, Ricardo Fernandes; Duarte, Aline Adelaide Paz da Silva; Boing, Fernanda; Ligabue, Rosane Angélica; Pagnoncelli, Rogério Miranda
Resumo
Objetivo: Incorporar o hormônio de crescimento recombinante humano em um polímero biodegradável (PLGA). Material e método: As matrizes foram confeccionadas através da técnica de evaporação de solventes. Foi feita uma mistura do polímero (poli ácido glicólico lático) e do hormônio do crescimento humano recombinante (Saizen® Merck Serono S.A. Aubonne, Suíça). Essa mistura foi vertida em moldes de silicone circulares de 1 cm de diâmetro e aproximadamente 2 mm de espessura, e levada para secagem em uma câmara de evaporação de solvente por 48 horas. Após esse período, as matrizes foram imersas em PBS e passaram por um banho termostatizado (ensaio de degradação hidrolítica), in vitro, à temperatura de 37°C. As amostras foram retiradas do banho no intervalo de 1, 2, 3, 4, 7, 10 e 14 dias. Foram aferidas a perda de massa, a variação do pH e a concentração do hormônio liberado em função do tempo. Resultado: A concentração do hormônio liberado em função do tempo foi aumentando até o terceiro dia. No quarto dia, houve uma queda e, no sétimo, ocorreu um aumento do hormônio liberado, estendendo-se até o décimo dia; no 14° dia, houve queda novamente. O pH teve uma queda brusca de 7,4 para 3,2 no primeiro dia, mantendo uma pequena queda até o 14° dia. A perda de massa foi gradual em relação ao tempo, como já era esperado. Conclusão: O PLGA é um bom biomaterial para confecção de matrizes com hormônio do crescimento. Revelou-se possível incorporar o rhGH nessa matriz, de modo a, então, desenvolver-se um substituto ósseo.
Palavras-chave
Abstract
Objective: Incorporate recombinant human growth hormone in a biodegradable polymer (PLGA). Material and method: The arrays were fabricated by solvent evaporation technique. A mixture of polymer (poly lactic glycolic acid) and recombinant human growth (Saizen® Merck Serono SA Aubonne, Switzerland) was performed hormone. This mixture was poured into circular molds silicone 01cm in diameter and about 02mm thick, and carried into a drying chamber for evaporation of solvent for 48 hours. After this period, the matrices were immersed in PBS and passed through a constant temperature bath (test for hydrolytic degradation) in vitro, at a temperature of 37°C. The samples were removed from the bath in the range of 01, 02, 03, 04, 07, 10, 14 days. Mass loss, pH and concentration of hormone released as a function of time was measured. Result: The concentration of hormone released versus time was increased until the third day. On the fourth day had a fall and on the seventh day there have been increased hormone released by the tenth day, the fourteenth day was falling again. The pH had a sharp drop from 7.4 to 3.2 on the first day and keeping a small drop until the fourteenth day. The mass loss was a gradual loss in relation to time as was to be expected. Conclusion: PLGA is a good biomaterial for making breeders of growth hormone. It has proved possible to incorporate the rhGH in the array so as to then develop a bone substitute.
Keywords
References
1. Soares AQ, Oliveira LF, Rabelo D, Souza AR. Polímeros biodegradáveis: novas perspectivas para ciências farmacêuticas. Revista Eletrônica de Farmácia. 2005;2(2 Supl):202-5.
2. Houchin ML, Topp EM. Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms. J Pharm Sci. 2008 Jul;97(7):2395-404. http://dx.doi.org/10.1002/jps.21176. PMid:17828756.
3. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm. 2000 Jul;50(1):147-60. http://dx.doi.org/10.1016/S0939-6411(00)00084-9. PMid:10840198.
4. Li X, Zhang Y, Yan R, Jia W, Yuan M, Deng X, et al. Influence of process parameters on the protein stability encapsulated in poly-DL-lactide-poly(ethylene glycol) microspheres. J Control Release. 2000 Jul;68(1):41-52. http://dx.doi.org/10.1016/S0168-3659(00)00235-2. PMid:10884578.
5. Ohlsson C, Bengtsson B-Å, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev. 1998 Fev;19(1):55-79. PMid:9494780.
6. Zhao L, He C, Gao Y, Cen L, Cui L, Cao Y. Preparation and cytocompatibility of PLGA scaffolds with controllable fiber morphology and diameter using electrospinning method. J Biomed Mater Res B Appl Biomater. 2008 Out;87(1):26-34. http://dx.doi.org/10.1002/jbm.b.31060. PMid:18384158.
7. Calvo-Guirado JL, Mate-Sanchez J, Delgado-Ruiz R, Ramirez-Fernández MP, Cutando-Soriano A, Peña M. Effects of growth hormone on initial bone formation around dental implants: a dog study. Clin Oral Implants Res. 2011 Jun;22(6):587-93. http://dx.doi.org/10.1111/j.1600-0501.2010.02007.x. PMid:21121954.
8. Gómez-Moreno G, Cutando A, Arana C, Worf CV, Guardia J, Muñoz F, et al. The effects of growth hormone on the initial bone formation around implants. Int J Oral Maxillofac Implants. 2009 Nov-Dez;24(6):1068-73. PMid:20162111.
9. Jahno VD, Ribeiro GB, Santos LA, Ligabue R, Einloft S, Ferreira MR, et al. Chemical synthesis and in vitro biocompatibility tests of poly (L-lactic acid). J Biomed Mater Res A. 2007 Out;83(1):209-15. http://dx.doi.org/10.1002/jbm.a.31210. PMid:17437300.
10. Somatropina humana recombinante 4 UI. Saizen (pó liófilo injetável). Responsável técnico: AJG Guimarães. Buenos Aires: Bio Sidus; 2009. Bula de remédio: N1281212B.
11. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011 Set;3(3):1377-97.
12. Zhao J, Han W, Chen H, Tu M, Zeng R, Shi Y, et al. Preparation, structure and crystallinity of chitosan nano-fibers by a solid–liquid phase separation technique. Carbohydr Polym. 2011 Fev;83(4):1541-6. http://dx.doi.org/10.1016/j.carbpol.2010.10.009.
13. American Society for Testing and Materials – ASTM. Standard test method for in vitro degradation testing of hydrolytically degradable polymer resins and fabricated forms for surgical implants. Philadelphia: Standards Worldwide; 2010.
14. Kwak HH, Shim WS, Choi MK, Son MK, Kim YJ, Yang HC, et al. Development of a sustained-release recombinant human growth hormone formulation. J Control Release. 2009 Jul;137(2):160-5. http://dx.doi.org/10.1016/j.jconrel.2009.03.014. PMid:19332090.
15. Li W-J, Laurencin CT, Caterson EJ, Tuan RS, Ko FK. Electrospun nanofibrous structure: a novel scaffold for tissue engineering. J Biomed Mater Res. 2002 Jun;60(4):613-21. http://dx.doi.org/10.1002/jbm.10167. PMid:11948520.
16. Nur-E-Kamal A, Ahmed I, Kamal J, Schindler M, Meiners S. Three-dimensional nanofibrillar surfaces promote self-renewal in mouse embryonic stem cells. Stem Cells. 2006 Fev;24(2):426-33. http://dx.doi.org/10.1634/stemcells.2005-0170. PMid:16150921.
17. Woo KM, Chen VJ, Ma PX. Nano-fibrous scaffolding architecture selectively enhances protein adsorption contributing to cell attachment. J Biomed Mater Res A. 2003 Nov;67(2):531-7. http://dx.doi.org/10.1002/jbm.a.10098. PMid:14566795.
18. Raschke M, Rasmussen MH, Govender S, Segal D, Suntum M, Christiansen JS. Effects of growth hormone in patients with tibial fracture: a randomised, double-blind, placebo-controlled clinical trial. Eur J Endocrinol. 2007 Mar;156(3):341-51. http://dx.doi.org/10.1530/EJE-06-0598. PMid:17322494.
19. Tresguerres IF, Blanco L, Clemente C, Tresguerres JA. Effects of local administration of growth hormone in peri-implant bone: an experimental study with implants in rabbit tibiae. Int J Oral Maxillofac Implants. 2003 Nov-Dez;18(6):807-11. PMid:14696655.
20. Fallucco MA, Carstens MH. Primary reconstruction of alveolar clefts using recombinant human bone morphogenic protein-2: clinical and radiographic outcomes. J Craniofac Surg. 2009 Set;20(Supl 2):1759-64. http://dx.doi.org/10.1097/SCS.0b013e3181b5d08e. PMid:19816345.
21. Jung RE, Windisch SI, Eggenschwiler AM, Thoma DS, Weber FE, Hämmerle CHF. A randomized controlled critical trial evaluating clinical radiological outcomes after 3 and 5 years of dental placed in bone regenered by means of GBR techniques with or without the of BMP-2. Clin Oral Implants Res. 2009 Mar; 20(7):660-6. http://dx.doi.org/10.1111/j.1600-0501.2008.01648.x. PMid:19489935.
22. Dickinson BP, Ashley RK, Wasson KL, O’Hara C, Gabbay J, Heller JB, et al. Reduced morbidity and improved healing with bone morphogenic protein-2 in older patients with alveolar cleft defects. Plast Reconstr Surg. 2008 Jan;121(1):209-17. http://dx.doi.org/10.1097/01.prs.0000293870.64781.12. PMid:18176223.
23. Cho BC, Kim JY, Lee JH, Chung HY, Park JW, Roh KH, et al. The bone regenerative effect of chitosan microsphere-encapsulated growth hormone on bony consolidation in mandibular distraction osteogenesis in a dog model. J Craniofac Surg. 2004 Mar;15(2):299-311, discussion 312-3. http://dx.doi.org/10.1097/00001665-200403000-00028. PMid:15167253.
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email